Zydus Lifesciences has received approval from Health Canada for its generic Mesalamine suppositories, 1000 mg. These suppositories are indicated for treating mildly to moderately active ulcerative proctitis. According to IQVIA data from June 2025, annual sales for Mesalamine suppositories in Canada reached CAD 4.86 million. This approval will allow Zydus to manufacture and distribute this medication, expanding their product offerings in the Canadian market.
Health Canada Approves Mesalamine Suppositories
Zydus Lifesciences Limited has announced that it has received Notice of Compliance (NOC) from Health Canada for its generic Mesalamine suppositories 1000 mg. This approval enables the company to manufacture and market this product in the Canadian market.
Treatment Indication
The Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.
Manufacturing and Market Data
The Mesalamine suppositories will be manufactured at Zydus Lifesciences Ltd. in Changodar, Ahmedabad, Gujarat, India. According to IQVIA MAT June 2025, the annual sales of Mesalamine suppositories in Canada were CAD 4.86 million.
Source: BSE
